Lotte Biologics to Present Advanced ADC Platform Technology at Global Cancer Research Forum

Lotte Biologics is set to make a significant impact at the prestigious American Association for Cancer Research (AACR) annual meeting in San Diego. The company, in collaboration with Kanaph Therapeutics, will unveil groundbreaking research on its innovative ADC (Antibody-Drug Conjugate) platform technology, dubbed 'SoluFlex Link.' This presentation at one of the world's leading cancer research conferences underscores Lotte Biologics' commitment to advancing cancer therapeutics.

“

SoluFlex Link can maintain stable quality during distribution and storage.

The SoluFlex Link technology has demonstrated remarkable potential in preclinical studies. Research findings highlight its superior structural stability, particularly in preventing aggregation over time, a common challenge with existing ADC technologies. Unlike control groups where aggregation increased, the SoluFlex Link application showed significant inhibition, maintaining high stability. This enhanced stability is crucial for ensuring the quality and efficacy of ADCs during distribution and storage.

Furthermore, cell-based experiments targeting various receptors, including EGFR and TROP-2, have yielded impressive results. The SoluFlex Link-applied ADCs exhibited potent anti-cancer effects even at lower concentrations compared to non-applied groups. Notably, the technology also showed excellent efficacy in triple-negative breast cancer cells, a notoriously difficult-to-treat form of the disease. These findings suggest that SoluFlex Link is not limited to specific antibodies but can serve as a versatile platform technology capable of improving pharmacokinetic properties and enhancing anti-cancer efficacy.

“

In animal experiments, it showed improved pharmacokinetics based on high stability, proving its potential as a platform technology that can improve excellent anti-cancer efficacy and pharmacokinetic characteristics beyond specific antibodies.

Lotte Biologics' presentation at AACR is more than just a scientific disclosure; it's a strategic move to position itself as a key player in the rapidly evolving field of ADC development. The company's ambition is clear: to provide robust solutions that empower partners and clients to successfully develop next-generation ADCs. By showcasing the advanced capabilities of SoluFlex Link, Lotte Biologics aims to attract collaborations and drive innovation in the fight against cancer, reinforcing South Korea's growing influence in the global biopharmaceutical landscape.

“

We will provide solutions so that partner companies or clients can successfully develop next-generation ADCs.